Skip to main content

Volume 6 Supplement 3

AIDS Vaccine 2009

P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response

Background

The variability of HIV and the appearance of escape mutants are a major obstacle for HIV/AIDS vaccine development. In previous phase I/II studies recombinant MVA-Nef and MVA-BN®-Polytope expressing conserved epitopes from multiple proteins of HIV-1 induced good and broad cellular immune responses and indicated an inhibitory effect on viral replication during treatment interruption (MVA-Nef). To further broaden the immune responses a new MVA-BN®-Multiantigen vaccine candidate expressing full length or truncated HIV-1 proteins (gag, pol, nef, tat, vpr, vpu, vif, rev) has been developed and tested for safety and immunogenicity.

Methods

Fifteen HIV-1 infected patients on HAART therapy with CD4 counts above 350/μl received 2 × 108 TCID50 MVA-BN®-Multiantigen at weeks 0, 4 and 12. Cellular immune responses against HIV-1 proteins were measured by IFN-gamma ELISPOT from PBMC preparations. Peptide pools consisted of overlapping peptides: three pools each for gag and pol, four pools for nef and three pools for the remaining proteins.

Results

13 out of 15 (87%) of the subjects generated new or increased HIV specific responses following vaccination independent of their vaccinia prevaccination status. Amongst these subjects 77% (10/13) elicited a response to at least two and 54% (7/13) to at least three HIV proteins. Gag induced the highest magnitude and responder rate. No response was seen against tat and vif.

Conclusion

This MVA-BN®-Multiantigen vaccine induced broad cellular immune responses in HIV-1 infected individuals against most of the expressed HIV proteins in the presence of existing anti-vector immunity. The high number of responders is encouraging and warrants further studies.

Author information

Affiliations

Authors

Corresponding author

Correspondence to D Schmidt.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Overton, T., Schmidt, D., Hain, J. et al. P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response. Retrovirology 6, P411 (2009). https://doi.org/10.1186/1742-4690-6-S3-P411

Download citation

Keywords

  • Cellular Immune Response
  • Vaccine Candidate
  • Vaccinia
  • Treatment Interruption
  • Responder Rate